Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01317017 · ClinicalTrials.gov registry record · Early Phase 1
Cell Responses to IFN-gamma
A Early Phase 1 study, sponsored by Rockefeller University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT01317017 is a Early Phase 1 study that was terminated before completion, run by Rockefeller University. The registered enrollment target is 2 participants.
The verdict
NCT01317017, a Early Phase 1 study, was terminated before completion, sponsored by Rockefeller University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
IFN-gamma is a central player in the development of psoriasis lesions, which can be involved a variety of cellular processes in the skin. Dendritic cells are important cells in driving inflammation in psoriasis through the induction of T cells that produce IL-17 in psoriasis. Injecting IFN-g into the skin can increase the numbers of T cells and also inflammatory DCs that produce cytokines involved in IL-17 production. Thus, the investigators hypothesize that the dendritic cells present in the skin after IFN-g injection polarize IL-17-producing T cells.
Interventions
- DRUG Actimmune
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01317017
The ClinicalTrials.gov registry entry for NCT01317017 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Actimmune is the first listed.
NCT01317017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01317017 about?
NCT01317017 is a clinical study titled "Cell Responses to IFN-gamma". IFN-gamma is a central player in the development of psoriasis lesions, which can be involved a variety of cellular processes in the skin. Dendritic cells are important cells in driving inflammation in psoriasis through the induction of T cells that produce IL-17 in psoriasis. Injecting IFN-g into th...
What is the current status of trial NCT01317017?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2010-07. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01317017?
The interventions under investigation include: Actimmune (DRUG).
Who is sponsoring clinical trial NCT01317017?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.